Table 1.
Baseline Clinical Characteristics
| N=1125 | CHA2DS2‐VASc Score | P Value | ABC‐Stroke Score (at 3 y) | P Value | ||||
|---|---|---|---|---|---|---|---|---|
| Low Risk | Medium Risk | High Risk | Low Risk | Medium Risk | High Risk | |||
| n=13 | n=50 | n=1062 | n=53 | n=489 | n=583 | |||
| Male sex, No. (%) | 13 (100.0) | 44 (88.0) | 502 (47.3) | <0.001 | 32 (60.4) | 253 (51.7) | 274 (47.0) | 0.085 |
| Age, median (IQR), y | 61 (55.5–63.5) | 63 (57.7–71.0) | 77 (72–81) | <0.001 | 67 (59–73) | 73 (67–78) | 79 (75–83) | <0.001 |
| Comorbidities, No. (%) | ||||||||
| Hypertension | 0 (0.0) | 16 (32.0) | 906 (85.3) | <0.001 | 33 (62.3) | 406 (83.0) | 483 (82.8) | 0.001 |
| Diabetes mellitus | 0 (0.0) | 3 (6.0) | 296 (27.9) | <0.001 | 12 (22.6) | 129 (26.4) | 158 (27.1) | 0.774 |
| Heart failure | 0 (0.0) | 3 (6.0) | 334 (31.5) | <0.001 | 7 (13.2) | 126 (25.8) | 204 (35.0) | <0.001 |
| History of stroke/TIA | 0 (0.0) | 0 (0.0) | 212 (20.0) | <0.001 | 0 (0.0) | 16 (3.3) | 196 (33.6) | <0.001 |
| Renal impairment | 1 (7.7) | 3 (6.0) | 113 (10.6) | 0.547 | 0 (0.0) | 30 (6.1) | 87 (14.9) | <0.001 |
| Coronary artery disease | 0 (0.0) | 3 (6.0) | 218 (20.5) | 0.008 | 11 (20.8) | 84 (17.2) | 126 (21.6) | 0.187 |
| Current smoking | 5 (38.5) | 7 (14.0) | 173 (16.3) | 0.090 | 12 (22.6) | 81 (16.6) | 92 (15.8) | 0.433 |
| Concomitant antiplatelet treatment | 1 (7.7) | 7 (14.0) | 200 (18.8) | 0.415 | 13 (24.5) | 64 (13.1) | 131 (22.5) | <0.001 |
| High‐sensitivity troponin T, ng/mL | 6.8 (4.9–10.5) | 9.2 (5.4–12.6) | 12.3 (8.1–18.6) | 0.005 | 5.1 (3.8–7.3) | 9.2 (6.6–13.0) | 16.0 (11.5–22.8) | <0.001 |
| NT‐proBNP, ng/mL | 339.4 (205.9–561.9) | 369.5 (158.2–552.9) | 635.4 (329.9–1074.5) | 0.084 | 62.8 (40.0–102.6) | 408.1 (233.1–584.0) | 946.6 (643.6–1464.0) | <0.001 |
| TTR at 6 mo, median (IQR), % | 80 (73–100) | 80 (60–100) | 80 (66–100) | 0.377 | 80 (60–83) | 80 (66–100) | 80 (60–100) | 0.001 |
| TTR <65% at 6 mo, No. (%) | 2 (15.4) | 13 (26.0) | 258 (24.3) | 0.726 | 15 (28.3) | 105 (21.5) | 153 (26.2) | 0.151 |
ABC‐stroke indicates age, biomarkers (N‐terminal fragment B‐type natriuretic peptide, high‐sensitivity troponin), and clinical history (prior stroke/transient ischemic attack); CHA2DS2‐VASc, cardiac failure or dysfunction, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (doubled)—vascular disease, age 65 to 74 years and sex category (female); IQR, interquartile range; NT‐proBNP, N‐terminal fragment B‐type natriuretic peptide; TIA, transient ischemic attack; TTR, time in therapeutic range.